-transparent.png){kind=logo}
Cytochrome P450-dependent arachidonic acid metabolism in human kidney cortex from several postmortem subjects has been characterized. Using HPLC and GC/MS, four cytochrome P450-arachidonic acid metabolites were tentatively but not unequivocally identified as epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHT) and 19- and 20-hydroxyeicosatetraenoic acids, suggesting the involvement of two major cytochrome P450 enzymes, epoxygenase and omega/omega-1 hydroxylases. This pattern of metabolism was similar to that found in rabbit and rat kidneys. The formation of these metabolites was dependent on the presence of NADPH and inhibited by IgG of NADPH-cytochrome P450 (c) reductase. Immunologic studies of renal cytochrome P450 epoxygenase demonstrated that antibodies prepared against human-purified hepatic cytochrome P450 epoxygenase recognized renal enzyme protein and inhibited the enzyme activity by 92%. In contrast, control immunoglobulin did not inhibit renal cytochrome P450 epoxygenase. Antibody inhibition of renal cytochrome P450 epoxygenase demonstrated a degree of conservation of both enzyme proteins between liver and kidney. Antibodies against lauric acid omega/omega-1 hydroxylases (P450 omega) inhibited the formation of omega/omega-1 hydroxylase products, 19- and 20-HETEs. Identical qualitative patterns of arachidonic acid metabolites were observed in all cortical microsomes studied. Interindividual variations were observed in the cytochrome P450-dependent arachidonic acid metabolism, and the activities ranged from 0.031 to 5.027 nmol arachidonic acid converted/mg protein/30 min. which is about a 150-fold difference. However, when the specific activities for total cytochrome P450-dependent arachidonic acid metabolism were calculated, two separate groups could be distinguished, high and low metabolizers of arachidonic acid.(ABSTRACT TRUNCATED AT 250 WORDS)
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
July 1999,
Biochemistry. Biokhimiia,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
January 1989,
Advances in experimental medicine and biology,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
October 1985,
Biochemical and biophysical research communications,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
June 2002,
Current opinion in lipidology,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
January 1987,
Agents and actions. Supplements,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
October 2000,
Hypertension (Dallas, Tex. : 1979),
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
March 1998,
The Journal of pharmacology and experimental therapeutics,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
December 2018,
Sheng li xue bao : [Acta physiologica Sinica],
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
September 2001,
Molecular and cellular biology,
M L Schwartzman, and
P Martasek, and
A R Rios, and
R D Levere, and
K Solangi, and
A I Goodman, and
N G Abraham
January 1993,
Journal of lipid mediators,
